Swiss National Bank raised its stake in Endologix, Inc. (NASDAQ:ELGX) by 14.3% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 137,900 shares of the medical instruments supplier’s stock after acquiring an additional 17,300 shares during the quarter. Swiss National Bank owned approximately 0.17% of Endologix worth $670,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Marshall Wace North America L.P. raised its holdings in shares of Endologix by 277.3% in the second quarter. Marshall Wace North America L.P. now owns 173,939 shares of the medical instruments supplier’s stock worth $870,000 after acquiring an additional 127,838 shares during the last quarter. Accredited Investors Inc. acquired a new position in shares of Endologix in the second quarter worth $486,000. Rhumbline Advisers raised its holdings in shares of Endologix by 0.4% in the second quarter. Rhumbline Advisers now owns 95,581 shares of the medical instruments supplier’s stock worth $465,000 after acquiring an additional 381 shares during the last quarter. Schwab Charles Investment Management Inc. raised its holdings in shares of Endologix by 10.5% in the second quarter. Schwab Charles Investment Management Inc. now owns 321,309 shares of the medical instruments supplier’s stock worth $1,562,000 after acquiring an additional 30,429 shares during the last quarter. Finally, Pictet Asset Management Ltd. raised its holdings in shares of Endologix by 2.1% in the second quarter. Pictet Asset Management Ltd. now owns 894,318 shares of the medical instruments supplier’s stock worth $4,311,000 after acquiring an additional 18,110 shares during the last quarter.

TRADEMARK VIOLATION NOTICE: “Swiss National Bank Has $670,000 Stake in Endologix, Inc. (ELGX)” was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this story on another site, it was illegally stolen and reposted in violation of international copyright legislation. The legal version of this story can be viewed at https://www.dailypolitical.com/2017/10/23/swiss-national-bank-has-670000-stake-in-endologix-inc-elgx.html.

Endologix, Inc. (NASDAQ ELGX) opened at 5.10 on Monday. The company has a 50-day moving average price of $4.79 and a 200 day moving average price of $5.21. Endologix, Inc. has a 1-year low of $4.08 and a 1-year high of $12.74. The firm’s market capitalization is $425.51 million.

Endologix (NASDAQ:ELGX) last issued its earnings results on Wednesday, August 2nd. The medical instruments supplier reported ($0.10) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $0.08. The business had revenue of $48.60 million during the quarter, compared to analysts’ expectations of $47.58 million. Endologix had a negative return on equity of 46.32% and a negative net margin of 40.77%. Endologix’s revenue was down 4.6% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.20) earnings per share. Equities analysts anticipate that Endologix, Inc. will post ($0.62) earnings per share for the current year.

ELGX has been the subject of a number of analyst reports. Royal Bank Of Canada reissued a “hold” rating and issued a $5.00 price target on shares of Endologix in a report on Monday, July 31st. Canaccord Genuity reissued a “hold” rating on shares of Endologix in a report on Friday, August 4th. BidaskClub cut Endologix from a “hold” rating to a “sell” rating in a report on Friday, August 4th. Zacks Investment Research cut Endologix from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 25th. Finally, Stifel Nicolaus set a $6.00 price target on Endologix and gave the stock a “hold” rating in a report on Wednesday, August 2nd. Two equities research analysts have rated the stock with a sell rating and eleven have given a hold rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $6.28.

Endologix Company Profile

Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.

Want to see what other hedge funds are holding ELGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Endologix, Inc. (NASDAQ:ELGX).

Institutional Ownership by Quarter for Endologix (NASDAQ:ELGX)

Receive News & Ratings for Endologix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.